Slide 1: ATI-2138: An Investigational Novel Covalent ITK-JAK3 Inhibitor for T-Cell Mediated Diseases
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) EMPOWERING PATIENTS THROUGH KINOME INNOVATION 18 Sep 2023 ATI-2138: An Investigational Novel Covalent ITK-JAK3 Inhibitor for T-Cell Mediated Diseases
Slide 2: Cautionary Note Regarding Forward-Looking Statements
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Cautionary Note Regarding Forward-Looking Statements 2 Any statements contained in this presentation that do not describe historical facts may constitute forward-looki
Slide 3: ATI-2138: Combined ITK & JAK3 Inhibitor for Autoimmune Disease
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) ATI-2138: Combined IL-2-Inducible Tyrosine Kinase (ITK) & JAK3 Inhibitor for Autoimmune Disease 3 The unique pharmacological profile of ATI-2138 provides opportunity f
Slide 4: ATI-2138 is a Combined Covalent ITK & JAK3 Inhibitor for Autoimmune Disease
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) ATI-2138 is a Combined Covalent IL-2-Inducible Tyrosine Kinase (ITK) & JAK3 Inhibitor for Autoimmune Disease 4 1. Lechner KS, Neurath MF, Weigmann B. Role of the IL-2
Slide 5: Dose-Dependently Inhibited Inflammation in the Mouse T Cell Transfer Model of IBD
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) ATI-2138 Dose-Dependently Inhibited Inflammation in the Mouse T Cell Transfer Model of Inflammatory Bowel Disease 5 1. Study report SR03048; 2. CD4+CD45RB high naïve T
Slide 6: Phase 1 Multiple Ascending Dose Study Design
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) ATI-2138 Phase 1 Multiple Ascending Dose Study Design 6 1. Not part of dose escalation Eligibility • Healthy subjects age ranging between 18 and 55 years of age, inclu
Slide 7: Dose-dependent Inhibition of Both Exploratory PD Biomarkers Observed in MAD Study
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Dose-dependent Inhibition of Both ITK and JAK3 Exploratory PD Biomarkers was Observed in MAD Study 7 Source – Data on file • Pharmacodynamic biomarkers - Ex-vivo stimu
Slide 8: High Potency of ATI-2138 Observed in Preclinical Studies is Maintained in SAD/MAD Study
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) High Potency of ATI-2138 for ITK and JAK3 Observed in Preclinical Studies is Maintained in the SAD/MAD Clinical Study 8 1. Assay configured slightly different from cli
Slide 9: Multiple Ascending Dose: Preliminary Data Summary
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) ATI-2138 Multiple Ascending Dose: Preliminary Data Summary 9 • ATI-2138 was generally well tolerated at all doses tested in the trial. • No serious adverse events were
Slide 10: Initial Proof of Concept Trial in Ulcerative Colitis is Planned
© Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Acute Inflammatory Psoriasis Initial Proof of Concept Trial in Ulcerative Colitis is Planned 10 1. Lechner K et al. 2021. Gastroenterology;161(4):1270-1287.e19; 2. Stu